Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Source: CNBC
Original reporting
CNBC: read the full reportRelated stories
CNBC
AI build-out hits snag as Google and Microsoft put off raising capex forecasts
Microsoft and Alphabet both reported capital expenditures that fell short of estimates, adding to concern over the cost of the AI build-out.
CNBC
Alphabet earnings miss reflects first real sign that AI is taking a bite out of search
Wall Street hammered Alphabet for an earnings miss that included weaker-than-expected revenue out of the company's core business.
BBC Business
Poundland's future hangs in the balance as chain edges towards collapse
Poundland's bosses is filing a notice of intention to appoint administrators to the business.
CNBC
Hegseth reportedly fires U.S. top military planner as Trump downplays Iran peace talks
Lieutenant General Brett Sylvia was removed as head of strategy, plans and policy on the Joint Chiefs of Staff.
CNBC
Kalshi valuation jumps to $40 billion in latest funding round
The prediction market platform one year ago was valued at $5 billion.
CNBC
Warren urges DOJ criminal probe of Bank of America over anti-money-laundering violations
Warren asked the DOJ to disclose by Nov. 12 whether it has launched a criminal investigation into Bank of America after it admitted to violations.